Royal DSM N.V. and DuPont announce a joint venture called Actamax Surgical Materials LLC to develop, manufacture, and commercialize advanced surgical biomedical materials. The joint venture will address the large and underserved market of over 100 million annual surgical procedures worldwide by developing products like surgical sealants and tissue adhesives using patented biodegradable hydrogel technologies. DSM and DuPont will each own 50 percent of Actamax and combine their complementary capabilities, with DSM providing medical polymer processing and manufacturing and DuPont contributing materials science and biotechnology expertise.

1. Press Release
43E Heerlen (the Netherlands) / Wilmington (Delaware, United States), 23 September 2010
DSM and DuPont announce joint venture in surgical biomedical materials
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered
in the Netherlands, and DuPont announce an agreement to form a joint venture to
develop, manufacture and commercialize advanced surgical biomedical materials,
pending European Union regulatory approval. The joint venture will be named Actamax
Surgical Materials LLC. Under the joint venture agreement, DSM and DuPont will each
share a 50 percent interest.
The joint venture will address the market for surgical sealants, adhesion barriers and tissue
adhesives. This is a large and underserved market of over 100 million annual surgical
procedures worldwide. The outcome of many surgical procedures could be positively impacted
using next-generation materials under development by the joint venture.
Actamax Surgical Materials LLC will build a comprehensive biomedical product portfolio based
on several patent-protected biodegradable hydrogel technologies. The early technology
development was completed utilizing DuPont materials science and biotechnology capabilities.
Commercialization will rely on the medical polymer processing and manufacturing capabilities of
DSM.
The activities of the joint venture fit with the DSM biomedical materials portfolio in which the
company, through its DSM Biomedical unit, has rapidly built a leading position in the past few
years. Actamax Surgical Materials LLC is a strategic component of the DuPont Applied
BioSciences business, which integrates biotechnology with other sciences to create products
that can transform large, addressable markets. The joint venture will focus on the clinical
validation of the products and technology and commercialization will include manufacture and
sale of proprietary products as well as the establishment of joint development relationships with
leading device companies.
“The cooperation with DuPont is a great way to further boost our activities in the biomedical
field,” said Christophe J. Dardel, president DSM Biomedical. “In line with our open innovation
strategy, this will allow us to combine the strengths of two leading companies to develop
solutions to better address patient needs through material innovations.”
“Our platform of technologies will offer physicians and patients improved outcomes of surgery
that will prevent post-operative complications while reducing health care costs,” said John
Ranieri, vice president DuPont Applied BioSciences. “Actamax will deliver a number of products
that can be optimized for different surgical situations and clinical needs. The success DSM has
had in the biomedical materials market makes them an ideal strategic partner for us to
commercialize our technology portfolio.”
For more information, visit www.actamax.com.
1/2

2. Press Release
DuPont
DuPont (www.dupont.com) is a science-based products and services company. Founded in
1802, DuPont puts science to work by creating sustainable solutions essential to a better, safer,
healthier life for people everywhere. Operating in more than 90 countries, DuPont offers a wide
range of innovative products and services for markets including agriculture and food; building
and construction; communications; and transportation.
DSM – the Life Sciences and Materials Sciences Company
Royal DSM N.V. creates solutions that nourish, protect and improve performance. Its end
markets include human and animal nutrition and health, personal care, pharmaceuticals,
automotive, coatings and paint, electrical and electronics, life protection and housing. DSM
manages its business with a focus on the triple bottom line of economic performance,
environmental quality and social responsibility, which it pursues simultaneously and in parallel.
DSM has annual net sales of about € 8 billion and employs some 22,700 people worldwide. The
company is headquartered in the Netherlands, with locations on five continents. DSM is listed on
Euronext Amsterdam. More information: www.dsm.com.
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 45 5782595
e-mail media.relations@dsm.com e-mail investor.relations@dsm.com
DuPont Communications DuPont Investor Relations
Michelle Reardon Jeanmarie Desmond
Tel +1-302-695-7068 Tel +1-302-774-2229
michelle.s.reardon@usa.dupont.com jeanmarie.f.desmond@usa.dupont.com
DSM Forward-looking statements
This press release may contain forward-looking statements with respect to DSM’s future (financial) performance and
position. Such statements are based on current expectations, estimates and projections of DSM and information
currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties
that are difficult to predict and therefore it should be understood that many factors can cause actual performance and
position to differ materially from these statements. DSM has no obligation to update the statements contained in this
press release, unless required by law. The English language version of the press release is leading.
DuPont Forward-Looking Statements
This news release contains forward-looking statements based on management's current expectations, estimates and
projections. All statements that address expectations or projections about the future, including statements about the
company's strategy for growth, product development, market position, expected expenditures and financial results are
forward-looking statements. Some of the forward-looking statements may be identified by words like "expects,"
"anticipates," "plans," "intends," "projects," "indicates," and similar expressions. These statements are not guarantees
of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those
discussed more fully elsewhere in this release and in documents filed with the Securities and Exchange Commission
by DuPont, particularly its latest annual report on Form 10-K and quarterly report on Form 10-Q, as well as others,
could cause results to differ materially from those stated. These factors include, but are not limited to changes in the
laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates,
of countries in which the company does business; competitive pressures; successful integration of structural changes,
including restructuring plans, acquisitions, divestitures and alliances; cost of raw materials, research and development
of new products, including regulatory approval and market acceptance; seasonality of sales of agricultural products;
and severe weather events that cause business interruptions, including plant and power outages, or disruptions in
supplier and customer operations. The company undertakes no duty to update any forward-looking statements as a
result of future developments or new information.
2/2